- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | Lexeo Therapeutics GAAP EPS of -$0.30 misses by $0.01 | 1 | Seeking Alpha | ||
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.08. | Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights | 1.545 | GlobeNewswire (Europe) | Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first... ► Artikel lesen | |
| 12.08. | Lexeo Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08. | Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy | 215 | GlobeNewswire (Europe) | RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations... ► Artikel lesen | |
| 15.07. | What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple | 4 | Insider Monkey | ||
| 29.06. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.06. | Lexeo publishes phase I/II data for gene therapy LX2006 | 1 | Investing.com | ||
| 17.06. | Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia | 1 | GlobeNewswire (USA) | ||
| 15.06. | Why Is Lexeo Therapeutics Stock Gaining Monday? | 1 | Benzinga.com | ||
| 15.06. | Lexeo finalizes pivotal trial design for gene therapy LX2006 | 3 | Investing.com | ||
| 15.06. | Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia | 302 | GlobeNewswire (Europe) | SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design BLA supportive manufacturing... ► Artikel lesen | |
| 15.06. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.05. | Raymond James reiterates Strong Buy on Lexeo stock, $25 target | 7 | Investing.com | ||
| 11.05. | Lexeo Therapeutics GAAP EPS of -$0.25 | 1 | Seeking Alpha | ||
| 11.05. | Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights | 411 | GlobeNewswire (Europe) | SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine... ► Artikel lesen | |
| 11.05. | Lexeo Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.04. | Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | 5 | GlobeNewswire (USA) |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,871 | -0,14 % | Valneva: Strategische Weichenstellungen für die Zukunft des Biotech-Pioniers | ||
| NOVAVAX | 8,150 | +0,25 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 45,035 | +1,00 % | Why CRISPR Therapeutics Stock Rocked the Market Last Month | ||
| REGENERON PHARMACEUTICALS | 676,90 | +0,45 % | Here's Why The Fund Sold Regeneron Pharmaceuticals (REGN) | ||
| OCUGEN | 0,892 | +0,90 % | H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay | ||
| INOVIO PHARMACEUTICALS | 1,062 | -1,12 % | Inovio vor entscheidender FDA-Zulassung: Markteinführung von INO-3107 rückt näher | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | SANGAMO THERAPEUTICS, INC - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 27,800 | +0,72 % | Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. | ||
| INFLARX | 1,847 | +2,73 % | InflaRx NV: Innovativer Ansatz gegen Entzündungskrankheiten im Fokus der Investoren | ||
| INTELLIA THERAPEUTICS | 10,160 | +0,40 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| EDITAS MEDICINE | 2,330 | -0,43 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,130 | 0,00 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,006 | 0,00 % | TD Cowen startet Coverage für BioCryst mit Kaufempfehlung dank HAE-Medikament | ||
| NUREXONE BIOLOGIC | 0,388 | -5,83 % | 7 Jahre in den USA, 10 Jahre in Europa: Was der Orphan-Status für NurExone wirklich wert ist | ||
| ABIVAX | 101,00 | +0,60 % | Goldman Sachs initiates Abivax stock coverage with buy rating |
Das Unternehmen LEXEO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.